問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Medical Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 710Tainan CityTainan Yongkang

Recruiting Trial

145Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

421Cases

2020-04-01 - 2026-05-01

Phase III

Active
An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    BGB-A317 (Tislelizumab)和BGB-290 (Pamiparib)

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting3Sites

Terminated2Sites

2021-10-01 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

-

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2021-01-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2025-11-03 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-07-24 - 2027-01-31

Phase III

Active
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

  • Condition/Disease

    Myelodysplastic Syndrome (MDS)

  • Test Drug

    Venetoclax

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2021-05-20 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2011-05-01 - 2013-05-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-01-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2021-09-22 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

1 6 7 8 9 10 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB